🔍

HERANBA - Heranba Inds

📊 NSE: HERANBA 🏢 Pesticides / Agrochemicals - Indian 📅 Last Updated: 12/13/2025 22:53

📢 Recent Corporate Announcements

Heranba Industries to Convert ₹450 Cr ICDs into OFCDs of Subsidiary Heranba Organics

🟡 NEUTRAL ⭐ 6/10

M&A 📅 27 Apr 2026, 06:23 PM

Heranba Industries has approved the conversion of ₹450 crore in existing unsecured Inter-Corporate Deposits (ICDs) provided to its wholly-owned subsidiary, Heranba Organics Private Limited (HOPL), into Optionally Fully Convertible Debentures (OFCDs). This internal restructuring involves the issuance of 45 crore OFCDs at a face value of ₹10 each on a private placement basis. The transaction does not involve any fresh cash outflow and is designed to restructure the debt profile of the subsidiary. HOPL, which operates in the agrochemicals sector, showed significant growth with a turnover of ₹220.58 crore in FY 2024-25 compared to just ₹0.27 crore in the previous year.

Conversion of ₹450 crore unsecured ICDs into 45,00,00,000 OFCDs at a face value of ₹10 each
Target entity Heranba Organics Private Limited (HOPL) is a 100% material unlisted subsidiary
HOPL reported a substantial turnover increase to ₹220.58 crore in FY 2024-25 from ₹0.27 crore in FY 2023-24
The restructuring involves no fresh cash outflow and maintains 100% parent control
The transaction was conducted on an arm's-length basis as part of internal debt management

💡 As this is an internal financial restructuring with no cash outflow, it has no immediate impact on consolidated valuations. Investors should focus on the rapid scaling of the subsidiary HOPL as a potential future growth driver for the parent company.

Heranba Industries to Convert ₹450 Cr Subsidiary Loan into 10-Year Convertible Debentures

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 27 Apr 2026, 05:20 PM

Heranba Industries has approved the conversion of ₹450 crore in Inter-Corporate Deposits (ICDs) provided to its wholly-owned subsidiary, Heranba Organics Private Limited, into Optionally Fully Convertible Debentures (OFCDs). This restructuring formalizes the internal funding into a long-term instrument with a 10-year tenure and a nominal 1% annual interest rate. The OFCDs provide the parent company the option to convert the debt into equity shares of the subsidiary in the future. Since this is an internal transaction between a parent and its 100% subsidiary, it has no immediate impact on consolidated financial performance.

Conversion of ₹450 crore existing Inter-Corporate Deposits into Optionally Fully Convertible Debentures (OFCDs).
The new debentures carry a long-term tenure of 10 years.
The coupon rate is set at a nominal 1% per annum, significantly lower than market debt rates.
The transaction is aimed at restructuring existing inter-company funding on an arm's length basis.

💡 No immediate action is required as this is a balance sheet reclassification of existing internal funds. Investors should monitor the operational progress of the subsidiary, Heranba Organics, to evaluate the long-term value of the conversion option.

Heranba Launches New Crop Nutrition Products; Targets ₹2,500 Cr Revenue in FY26

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 10 Apr 2026, 03:39 PM

Heranba Industries has strategically entered the high-growth crop nutrition segment with the launch of two new products, Fentaamine and MycoHil, developed in collaboration with an American MNC. The company has set an ambitious total revenue target of ₹2,500 crore for the current fiscal year, supported by its entry into this segment which is growing at a 15% CAGR. Expansion plans also include establishing a subsidiary in Dubai to penetrate Middle Eastern and African markets. This diversification leverages Heranba's seven manufacturing facilities and aims to move beyond its core synthetic pyrethroids business.

Launched Fentaamine (bio-stimulant) and MycoHil (bio-fertilizer) in collaboration with a leading American MNC
Set an ambitious total revenue target of ₹2,500 crore for the current fiscal year
Targeting the crop nutrition segment which is growing at a CAGR of over 15% globally and in India
Plans to establish a subsidiary in Dubai to strengthen presence across 80+ countries
Leveraging 7 world-class manufacturing facilities to scale up CMO operations and brand equity

💡 Investors should monitor the company's ability to meet the ₹2,500 crore revenue guidance and the market's response to the new bio-stimulant products. The diversification into high-growth segments and global expansion via a Dubai subsidiary are strong positive indicators for long-term value.

Heranba Industries Announces Resignation of GM - Works Mahesh Kenjale

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 09 Apr 2026, 06:00 PM

Heranba Industries Limited has informed the exchanges regarding the resignation of Mr. Mahesh Kenjale, who served as the General Manager - Works. Designated as a Senior Management Personnel (SMP), his resignation will be effective from the close of business hours on April 30, 2026. The departure is attributed to his decision to pursue better professional opportunities. The company has stated it will ensure a smooth transition of his duties during the notice period.

Mr. Mahesh Kenjale resigns from the position of General Manager - Works.
The resignation is effective from April 30, 2026.
Mr. Kenjale was classified as Senior Management Personnel under SEBI Regulation 16(1)(d).
The reason for resignation is cited as pursuing better career opportunities.
The official intimation was filed with BSE and NSE on April 9, 2026.

💡 This is a routine management change at the operational level; investors should monitor for the appointment of a successor to ensure manufacturing stability.

Heranba Industries Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Mar 2026, 02:51 PM

Heranba Industries Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming financial results. The closure will remain in effect until 48 hours after the declaration of the audited financial results for the quarter and year ending March 31, 2026. The specific date for the board meeting to approve these results is yet to be announced.

Trading window closure effective from Wednesday, April 1, 2026
Closure relates to the audited financial results for the quarter and year ended March 31, 2026
Window to remain closed until 48 hours after the official results declaration
Applies to all designated persons, immediate relatives, and connected persons as per PIT Regulations

💡 This is a routine regulatory announcement with no direct impact on stock valuation. Investors should monitor for the upcoming board meeting date to prepare for the Q4 and FY26 earnings release.

Heranba Industries Faces ₹2.63 Crore Insolvency Petition Over Quality Dispute

🔵 WATCH ⭐ 6/10

LEGAL 📅 20 Mar 2026, 06:02 PM

Haresh Petrochem Private Limited has filed an insolvency application against Heranba Industries Limited under the IBC for a claim of approximately ₹2.63 Crores. Heranba has clarified that the payment was withheld due to quality issues with the goods supplied and is actively working to resolve the matter. The company expects to settle the dispute amicably outside of the NCLT proceedings. While the filing is a material event, the relatively small claim amount suggests it is a commercial dispute rather than a sign of systemic financial distress.

Insolvency petition filed under Section 9 of the IBC at NCLT Ahmedabad.
Claim amount involved is approximately ₹2.63 Crores.
Non-payment attributed to quality issues in goods/services provided by the petitioner.
Next hearing date for the matter is scheduled for April 20, 2026.
Management expects an out-of-court settlement with no long-term impact on operations.

💡 Investors should monitor the situation until the next hearing on April 20, 2026, to ensure a settlement is reached. Given the small claim size relative to Heranba's scale, this is likely a tactical legal move by a creditor rather than a solvency crisis.

IBC Insolvency Application Filed Against Heranba Subsidiary Over Rs 93.90 Lakh Claim

🔵 WATCH ⭐ 6/10

LEGAL 📅 27 Feb 2026, 04:13 PM

Haresh Petrochem Private Limited has filed an insolvency petition under the IBC against Heranba Organics Private Limited, a 100% subsidiary of Heranba Industries. The initial claim was approximately Rs 1.70 Crores, which has been reduced to an outstanding balance of Rs 93.90 Lakhs following part payments. The company states the remaining balance is withheld due to quality disputes regarding the supplied goods. Management expects to settle the matter amicably outside the NCLT framework once the quality issues are addressed.

Insolvency application filed under Section 9 of IBC against 100% subsidiary Heranba Organics.
Total claim amount reduced from Rs 1.70 Crores to an outstanding balance of Rs 93.90 Lakhs.
Payment withheld by the subsidiary due to unresolved quality issues with the petitioner's supplies.
Management expects an out-of-court settlement and does not anticipate long-term material impact.

💡 Monitor the progress of the NCLT proceedings to ensure the settlement is reached as planned. While the claim amount is small, any escalation in insolvency proceedings for a subsidiary requires caution.

Heranba Q3: Consolidated Net Loss Widens to ₹23.29 Cr; Standalone Profit at ₹9.32 Cr

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 07:41 PM

Heranba Industries reported a weak set of consolidated numbers for Q3 FY26, with the net loss widening to ₹23.29 crore from a loss of ₹10.37 crore in the same quarter last year. Consolidated revenue from operations declined to ₹305.17 crore, down from ₹341.29 crore year-on-year. While standalone operations turned profitable at ₹9.32 crore compared to a loss last year, the consolidated performance was dragged down by higher finance costs and depreciation. The company also announced the appointment of ZMAS and Associates as the new Internal Auditor.

Consolidated revenue from operations fell to ₹305.17 crore in Q3 FY26 from ₹341.29 crore in Q3 FY25.
Consolidated net loss widened significantly to ₹23.29 crore versus a loss of ₹10.37 crore YoY.
Standalone profit stood at ₹9.32 crore, a recovery from a standalone loss of ₹9.12 crore in the previous year's quarter.
Consolidated finance costs doubled to ₹12.39 crore from ₹6.15 crore in the year-ago period.
Consolidated depreciation and amortisation expenses rose sharply to ₹25.67 crore from ₹14.03 crore YoY.

💡 Investors should exercise caution as widening consolidated losses and rising finance costs indicate significant pressure on the bottom line. The divergence between standalone profit and consolidated loss suggests underperformance in subsidiary operations that requires further scrutiny.

Heranba Industries Appoints ZMAS and Associates as Internal Auditor for Tenure Ending March 2027

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 06:35 PM

Heranba Industries Limited has appointed ZMAS and Associates, Chartered Accountants, as its Internal Auditor. The appointment was approved by the Board of Directors on February 11, 2026, and covers the period from January 01, 2026, to March 31, 2027. This is a standard regulatory compliance measure under SEBI Listing Regulations to ensure internal financial controls. The firm, established in 2013, will be responsible for auditing the company's internal processes and governance frameworks.

Appointment of ZMAS and Associates (Firm Registration No. 136783W) as Internal Auditor.
The audit tenure is effective from January 01, 2026, through March 31, 2027.
Board approval for the appointment was granted during the meeting held on February 11, 2026.
The appointment complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 This is a routine administrative update with no direct impact on stock valuation; no specific action is required from investors. Continue to monitor the company's core business performance and quarterly earnings.

Heranba Q3 Results: Standalone Profit of ₹9.32 Cr; Consolidated Net Loss Widens to ₹23.29 Cr

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 06:13 PM

Heranba Industries reported a mixed Q3 FY26, with standalone operations turning profitable at ₹9.32 crore despite a 9.4% YoY revenue dip to ₹306.55 crore. However, the consolidated picture is concerning as net losses widened to ₹23.29 crore from ₹10.37 crore YoY. This deterioration is largely driven by a sharp spike in consolidated depreciation (₹25.67 crore vs ₹14.03 crore) and finance costs (₹12.39 crore vs ₹6.15 crore). The company also announced the appointment of ZMAS and Associates as internal auditors.

Standalone Net Profit of ₹9.32 crore vs a loss of ₹9.12 crore in Q3 FY25.
Consolidated Net Loss widened significantly to ₹23.29 crore from ₹10.37 crore YoY.
Consolidated Finance Costs surged 101% YoY to ₹12.39 crore.
Consolidated Depreciation and Amortization increased by 83% YoY to ₹25.67 crore.
Nine-month consolidated revenue showed growth at ₹1,235.58 crore vs ₹1,074.96 crore YoY.

💡 The widening consolidated loss despite standalone profitability suggests significant drag from subsidiaries or new capital expenditures not yet yielding returns. Investors should wait for management commentary on margin recovery and debt levels before taking new positions.

Heranba Subsidiary to Incorporate UAE Unit with INR 2 Crore Initial Investment

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 14 Jan 2026, 03:19 PM

Heranba Industries Limited has announced that its wholly-owned subsidiary, Mikusu India Private Limited, will establish a new 100% subsidiary in the United Arab Emirates. The new entity will focus on the agro-chemical business, specifically pesticides, insecticides, and herbicides. An initial cash investment of up to INR 2.00 crores is planned for this expansion. This strategic move aims to enhance the company's global footprint and distribution capabilities in the Middle East.

Board of Mikusu India Private Limited approved the 100% WOS in UAE on January 14, 2026.
Proposed initial investment in the UAE subsidiary is up to INR 2.00 crores in cash.
The entity will deal in chemical products including fungicides, weedicides, and pesticides.
RBI approval will be required for the remittance of Outward Direct Investment (ODI) post-inception.

💡 Investors should view this as a positive step toward international market penetration. Monitor the progress of the UAE subsidiary's incorporation and its eventual contribution to the company's export revenue.

Heranba Industries Reports 100% Demat Holding for Quarter Ended December 31, 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Jan 2026, 06:44 PM

Heranba Industries has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The company's Registrar, Bigshare Services, confirmed that no requests for dematerialization or rematerialization were received during the quarter ended December 31, 2025. Significantly, the Registrar noted that the entire shareholding of the company is already maintained in dematerialized form. This is a standard regulatory filing confirming the integrity of the company's share records.

Compliance certificate issued for the quarter ended December 31, 2025.
Registrar confirms that 100% of the company's shares are held in demat form.
Zero requests for dematerialization or rematerialization were processed during the period.
The filing follows the SEBI (Depositories and Participants) Regulations, 2018 requirements.

💡 No action is required from investors as this is a routine administrative filing. Continue to monitor the company's operational performance and upcoming quarterly financial results.

Heranba Industries to Close Trading Window from Jan 1, 2026, for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Dec 2025, 03:51 PM

Heranba Industries Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI insider trading regulations. This closure is ahead of the declaration of the company's financial results for the quarter ended December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be announced at a later date.

Trading window closure begins on January 1, 2026.
Closure is related to the financial results for the quarter ended December 31, 2025.
Window will reopen 48 hours after the official declaration of financial results.
Restriction applies to all designated persons and connected individuals under SEBI PIT Regulations.

💡 This is a routine regulatory filing with no impact on company fundamentals; investors should monitor for the upcoming Q3 FY26 earnings date.

View All HERANBA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total consolidated segment revenue for H1 FY26 reached INR 974.14 Cr, representing a 32.77% growth compared to INR 733.67 Cr in H1 FY25. A major business segment contributed INR 255.30 Cr, or 26.21% of total revenue, during H1 FY26.

Geographic Revenue Split

Export revenue contribution has moderated from 45% in FY23 to approximately 28-30% in FY25 due to global demand slowdown. Domestic revenue is supported by a pan-India network of 9,500+ dealers and 21+ depots.

Profitability Margins

Net profit margins are projected to stabilize at 5-6% in the next fiscal year. Consolidated Profit Before Tax (PBT) for H1 FY26 was INR 18.86 Cr, a 71.67% decline from INR 66.57 Cr in H1 FY25, impacted by a 74% increase in depreciation and a 127% rise in interest costs.

EBITDA Margin

EBITDA margins were suppressed at 5.4% for 9M FY25 due to lower product realizations and macro headwinds. Management targets a recovery to 12-14% EBITDA margin for the next fiscal year.

Capital Expenditure

Property, Plant, and Equipment (PPE) increased to INR 730.59 Cr as of September 30, 2025, from INR 662.34 Cr in March 2025. Significant investments are focused on the Sarigam Phase 2 and Saykha facilities.

Credit Rating & Borrowing

The company maintains a 'CRISIL A/Stable' rating (outlook revised from Positive) and 'CRISIL A1' for short-term facilities. Gearing remains low at 0.07 times, though interest expenses rose to INR 23.88 Cr in H1 FY26 from INR 10.49 Cr YoY.

⚙️ Operational Drivers

Raw Materials

Key raw materials include chemical intermediates for Technicals, Formulations, and Intermediates, which constitute the bulk of the 350+ products commercialized.

Import Sources

Not explicitly disclosed, but the company exports to 65+ countries across Asia, Africa, Middle East, and Southeast Asia, suggesting global sourcing and distribution links.

Capacity Expansion

Sarigam Phase 1 started commercial production in Q2 FY25. Sarigam Phase 2 and the Saykha facility are both expected to commence commercial production by the end of Q4 FY25.

Raw Material Costs

Raw material costs are impacted by lower realizations in the technical business. Provision for doubtful receivables increased to INR 8.26 Cr in H1 FY26 from INR 0.65 Cr YoY, reflecting credit environment challenges.

Manufacturing Efficiency

Manufacturing efficiency is currently impacted by lower realizations and the transitionary phase of new CAPEX; depreciation rose 74% YoY to INR 46.99 Cr as new assets were capitalized.

Logistics & Distribution

Distribution is handled through a network of 9,500+ dealers, supporting domestic revenue growth despite international headwinds.

📈 Strategic Growth

Expected Growth Rate

10.50%

Growth Strategy

Growth will be driven by operationalizing Sarigam Phase 2 and Saykha facilities by Q4 FY25, adding new product registrations, and expanding the customer base. The company aims to leverage its integrated 'Technicals to Formulations' model to capture market share as prices bottom out.

Products & Services

Agrochemical Technicals, Formulations, and Intermediates, including Synthetic Pyrethroids and branded domestic formulations.

Brand Portfolio

Heranba, Mikusu India, Daikaffil Chemicals.

New Products/Services

The company is looking to add new product registrations to drive the 'next wave of growth' following the completion of current CAPEX cycles.

Market Expansion

Expansion into 65+ countries and strengthening the domestic presence through 9,500+ dealers and new manufacturing hubs in Saykha and Sarigam.

Market Share & Ranking

Heranba is one of the leading players in the Indian agrochemicals industry with a diversified product mix.

Strategic Alliances

The group includes subsidiaries Mikusu India Private Limited, Heranba Organics Private Limited, and step-down subsidiary Daikaffil Chemicals India Limited.

🌍 External Factors

Industry Trends

The agrochemical industry is currently in a 'transitionary year' characterized by price bottoming and inventory destocking. Future growth is expected from integrated players with strong registration pipelines.

Competitive Landscape

Competes with other large-scale agrochemical manufacturers in both the technical export market and the domestic branded formulation market.

Competitive Moat

The moat is built on integrated operations (Technicals to Formulations), a massive network of 9,500+ dealers, and a portfolio of 350+ commercialized products, which are difficult for new entrants to replicate quickly.

Macro Economic Sensitivity

Highly sensitive to global agrochemical demand cycles and domestic monsoon patterns affecting the formulation business.

Consumer Behavior

Shift toward branded formulations in the domestic market is supporting revenue, while international B2B customers are currently focused on inventory destocking.

Geopolitical Risks

Challenging global macros and trade conditions have already reduced export revenue share by approximately 15 percentage points since FY23.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by SEBI (LODR) Regulations and agrochemical manufacturing standards, including CIB&RC registrations for new products.

Environmental Compliance

Operations are subject to pollution control norms at GIDC Vapi, Sarigam, and Saykha; no specific ESG cost figures were provided.

Taxation Policy Impact

The company follows Indian Accounting Standards (Ind AS); specific tax rate impacts were not detailed beyond standard corporate tax applications.

Legal Contingencies

Auditors reported no matters causing belief that financial results have not disclosed required information under Regulation 33 of the Listing Regulations.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the timeline for the recovery of international demand, which could keep EBITDA margins suppressed below the 12-14% target if destocking persists.

Geographic Concentration Risk

Approximately 70% of revenue is now domestic, increasing sensitivity to Indian agricultural cycles, while 30% remains exposed to 65+ international markets.